NCT06668831 Fibroblast Growth Factor 23 and Risk of Cardiac Arrhythmias in Hemodialysis Patients
| NCT ID | NCT06668831 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Antonio Bellasi |
| Condition | Hemodialysis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-10-12 |
| Primary Completion | 2025-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2024-10-12 with a primary completion date of 2025-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Despite recent progress in the field of hemodialysis (HD), mortality remains unacceptably high, particularly due to cardiac arrhythmias. Recent evidence suggests that fibroblast growth factor 23 (FGF23) is implicated in the pathogenesis of cardiac arrhythmias and sudden death. However, several aspects of both the pathogenetic mechanism(s) as well as the actual association in individuals with Chronic Kidney Disease (CKD) and the effect of dialysis clearance of FGF23 need to be elucidated. The investigators aim at testing the independent association of FGF23 changes due to dialysis removal and electrocardiographic (ECG) abnormalities (namely QTc prolongation) in a well characterized sample of patients undergoing maintenance HD. The study will be developed in the Division of Nephrology, Ente Ospedaliero Cantonale.
Eligibility Criteria
The study envisages the enrolment of: * Adult subjects (\>18 years of age) who can sign an informed consent. * on maintenance HD (for at least 3 months) Exclusion Criteria: * history of cardiac arrhythmias at study recruitment define as atrial fibrillation or pace-maker assisted cardiac rhythm
Contact & Investigator
Antonio Bellasi, MD, PhD
PRINCIPAL INVESTIGATOR
Ente Ospedaliero Cantonale, Bellinzona
Frequently Asked Questions
Who can join the NCT06668831 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hemodialysis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06668831 currently recruiting?
Yes, NCT06668831 is actively recruiting participants. Contact the research team at antonio.bellasi@eoc.ch for enrollment information.
Where is the NCT06668831 trial being conducted?
This trial is being conducted at Lugano, Switzerland.
Who is sponsoring the NCT06668831 clinical trial?
NCT06668831 is sponsored by Antonio Bellasi. The principal investigator is Antonio Bellasi, MD, PhD at Ente Ospedaliero Cantonale, Bellinzona. The trial plans to enroll 30 participants.